ArticleProtoplasma2026
Artificial MicroRNA delivery and gene silencing via extracellular vesicles derived from molecularly modified tobacco.
Article in Protoplasma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plant-Derived Nanovesicles: A Comprehensive Review from Isolation to Clinical Translation-Unlocking Natural Nanocarriers for Biomedical Applications.Biomolecules · 2026Review
- Cellular demiurgs - engineer to understand.Protoplasma · 2026Article
- Plant-derived extracellular vesicles for drug delivery: current and future.Regenerative biomaterials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are emerging as biocompatible carriers for RNA-based delivery in both plant and non-plant systems. In this study, we present the first demonstration that EVs derived from plants can be engineered to deliver artificial microRNAs (amiRNAs) and induce gene silencing in planta. Molecularly modified Nicotiana tabacum plants were generated to express an amiRNA which was designed to target the enhanced green fluorescent protein (EGFP) gene. EVs isolated from tobacco plants expressing amiR-GFP were 100–200 nm in diameter and exhibited selective enrichment of the amiRNA at levels comparable to endogenous miR167a and miR168a. Functional assays demonstrated that these EVs were efficiently internalized by EGFP-expressing tobacco protoplasts and intact leaves, leading to a reduction in EGFP expression, as confirmed by fluorescence microscopy and RT-qPCR. Suppression of GFP fluorescence was more rapid in protoplasts and became evident within the first hour post-application, whereas in leaves, a significant effect appeared closer to two hours. These findings establish that plant-derived EVs can be programmed to deliver amiRNAs, highlighting their potential for future applications in plant biotechnology and RNA-based delivery platforms.
Indexed as
Identifiers
41366159What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.